These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 1096771)

  • 21. Immunotherapy with a recombinant hybrid molecule alleviates allergic responses more efficiently than an allergenic cocktail or pollen extract in a model of chenopodium album allergy.
    Nouri HR; Sankian M; Afsharzadeh D; Varasteh A
    Int Arch Allergy Immunol; 2013; 161(4):325-32. PubMed ID: 23689669
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of hyposensitization for tree pollinosis on associated apple allergy.
    Herrmann D; Henzgen M; Frank E; Rudeschko O; Jäger L
    J Investig Allergol Clin Immunol; 1995; 5(5):259-67. PubMed ID: 8574432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulatory control and standardization of allergenic extracts. Clinical methods of evaluation of extracts.
    Norman PS
    Arb Paul Ehrlich Inst Georg Speyer Haus Ferdinand Blum Inst Frankf A M; 1983; (78):65-9. PubMed ID: 6625586
    [No Abstract]   [Full Text] [Related]  

  • 24. Injection therapy for asthma and allergic rhinitis.
    Deamer WC
    Pediatr Clin North Am; 1969 Feb; 16(1):243-55. PubMed ID: 5766662
    [No Abstract]   [Full Text] [Related]  

  • 25. The use of grass pollen-specific immunotherapy among grass pollen allergic rhinitis in the general population.
    Linneberg A; Bødtger U
    Allergy; 2007 Jul; 62(7):825-6. PubMed ID: 17573735
    [No Abstract]   [Full Text] [Related]  

  • 26. [Desensitization by the extemporaneous combination of aluminum hydroxide with allergens (delayed-action allergens)].
    Wolfromm R; Vallery-Radot C; Guibert L; Zalman Z
    Acta Allergol; 1969 Sep; 24(3):202-15. PubMed ID: 5395957
    [No Abstract]   [Full Text] [Related]  

  • 27. [Hyposensitization treatment of allergic diseases].
    Wüthrich B
    Schweiz Rundsch Med Prax; 1993 May; 82(18):529-33. PubMed ID: 8497762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of allergenicity and immunogenicity of an intact allergen vaccine and commercially available allergoid products for birch pollen immunotherapy.
    Lund L; Henmar H; Würtzen PA; Lund G; Hjortskov N; Larsen JN
    Clin Exp Allergy; 2007 Apr; 37(4):564-71. PubMed ID: 17430354
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy with alginate-conjugated two grass pollen extract in patients with allergic rhinoconjunctivitis.
    Tari MG; Mancino M; Pozzuoli G; Mauro B; Verga A; Monti G
    Allergol Immunopathol (Madr); 1990; 18(1):35-40. PubMed ID: 2382596
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allergen immunotherapy with the hypoallergenic B-cell epitope-based vaccine BM32 modifies IL-10- and IL-5-secreting T cells.
    Rauber MM; Möbs C; Campana R; Henning R; Schulze-Dasbeck M; Greene B; Focke-Tejkl M; Weber M; Valenta R; Pfützner W
    Allergy; 2020 Feb; 75(2):450-453. PubMed ID: 31330050
    [No Abstract]   [Full Text] [Related]  

  • 31. Simultaneous SCIT with 2 separate allergen extracts demonstrates comparable safety compared to SCIT with a single allergen extract.
    Röder A; Darrelmann N; Klingenberg W; Krüll M; Suttorp N; Noga O
    J Investig Allergol Clin Immunol; 2009; 19(6):512-3. PubMed ID: 20128433
    [No Abstract]   [Full Text] [Related]  

  • 32. Immunologic effects of encapsulated short ragweed extract: a potent new agent for oral immunotherapy.
    Litwin A; Flanagan M; Entis G; Gottschlich G; Esch R; Gartside P; Michael JG
    Ann Allergy Asthma Immunol; 1996 Aug; 77(2):132-8. PubMed ID: 8760779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of sublingual immunotherapy with a monomeric allergoid in very young children.
    Agostinis F; Tellarini L; Canonica GW; Falagiani P; Passalacqua G
    Allergy; 2005 Jan; 60(1):133. PubMed ID: 15575951
    [No Abstract]   [Full Text] [Related]  

  • 34. Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy.
    Kahlert H; Suck R; Weber B; Nandy A; Wald M; Keller W; Cromwell O; Fiebig H
    Int Arch Allergy Immunol; 2008; 145(3):193-206. PubMed ID: 17912007
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Study on specific immunotherapy with the aid of 3M Diagnostic Systems' tests.
    Stasiak-Barmuta A; Dabrowska I; Piotrowska T; Hofman J
    Pneumonol Alergol Pol; 1992; 60 Suppl 1():53-6. PubMed ID: 1292848
    [No Abstract]   [Full Text] [Related]  

  • 36. Specific immunotherapy.
    Larché M
    Br Med Bull; 2000; 56(4):1019-36. PubMed ID: 11359635
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sublingual immunotherapy.
    Corrigan C
    J Allergy Clin Immunol; 2007 Feb; 119(2):515; author reply 515-7. PubMed ID: 17187850
    [No Abstract]   [Full Text] [Related]  

  • 38. Safety of sublingual grass pollen immunotherapy after anaphylaxis.
    Nichani JR; de Carpentier J
    J Laryngol Otol; 2009 Jun; 123(6):683-4. PubMed ID: 18501039
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Immunological and clinical studies on the pollen-L-tyrosin complexes in hyposensitization therapy].
    Horak F
    Wien Med Wochenschr; 1977 Nov; 127(22):677-81. PubMed ID: 595610
    [No Abstract]   [Full Text] [Related]  

  • 40. Oral allergy syndrome in patients with airborne pollen allergy treated with specific immunotherapy.
    Czarnecka-Operacz M; Jenerowicz D; Silny W
    Acta Dermatovenerol Croat; 2008; 16(1):19-24. PubMed ID: 18358104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.